| 15 Nov 2009 - Chemotargets signs drug discovery contract with Omnia Molecular |
| Chemotargets and Omnia Molecular, a Barcelona-based biotech company focussed on the discovery of new anti infectives, have signed an agreement by which Chemotargets will apply its proprietary structure-based methodology to design compounds against a panel of aminoacyl-tRNA synthetases. These compounds will be screened by means of a proprietary cutting edge technology developed by Omnia Molecular. |